Metadata

Name CCU002_01 Anticoagulant medication
Type Disease or Syndrome
Group Disease or Syndrome
Data Sources





Clinical Terminologies British National Formulary (BNF)
Codelists covid_impact_ccu00201_anticoagulant_England_BNF.csv
Valid Event Data Range 01/01/1997 - 07/12/2020
Sex Female
Male
Authors Rochelle Knight, Venexia Walker, Samantha Ip, Jennifer A Cooper, Thomas Bolton, Spencer Keene, Rachel Denholm, Ashley Akbari, Hoda Abbasizanjani, Fatemeh Torabi, Efosa Omigie, Sam Hollings, Teri-Louise North, Renin Toms, Emanuele Di Angelantonio, Spiros Denaxas,, Johan H Thygesen, Christopher Tomlinson, Ben Bray, Craig J Smith, Mark Barber, George Davey Smith, Nishi Chaturvedi, Cathie Sudlow, William N Whiteley, Angela Wood, Jonathan A C Sterne,, CVD-COVID-UK/COVID-IMPACT consortium, Longitudinal Health and Wellbeing COVID-19 National Core Study
Agreement Date 24 Nov 2021
Version (UUID) Revision 1 (COVID-IMPACT)

Phenotypes

England primary care EHR: Anticoagulant medication

terminology code term
BNF 0208020Y0AAAEAE Rivaroxaban 15mg tablets and Rivaroxaban 20mg tablets
BNF 0208020X0AAAAAA Dabigatran etexilate 75mg capsules
BNF 0208020V0AABBBB Warfarin 1mg/ml oral suspension sugar free
BNF 0208020X0AAACAC Dabigatran etexilate 150mg capsules
BNF 0208020X0AAABAB Dabigatran etexilate 110mg capsules
BNF 0208020Y0BBAAAA Xarelto 10mg tablets
BNF 0208020V0AAASAS Warfarin 500microgram tablets
BNF 0208020V0AAAMAM Warfarin 3mg/5ml oral liquid
BNF 0208020V0BBAFAS Marevan 500microgram tablets
BNF 0208020V0AAAIAI Warfarin 5mg/5ml oral liquid
BNF 0208020H0AAAAAA Acenocoumarol 1mg tablets
BNF 0208020N0AAACAC Phenindione 50mg tablets
BNF 0208020Y0AAAAAA Rivaroxaban 10mg tablets
BNF 0208020N0AAABAB Phenindione 25mg tablets
BNF 0208020Y0AAADAD Rivaroxaban 2.5mg tablets
BNF 0208020Y0AAACAC Rivaroxaban 20mg tablets
BNF 0208020Y0AAABAB Rivaroxaban 15mg tablets
BNF 0208020Z0AAAAAA Apixaban 2.5mg tablets
BNF 0208020X0BBACAC Pradaxa 150mg capsules
BNF 0208020V0AAAAAA Warfarin 1mg tablets
BNF 0208020AABBAAAA Lixiana 15mg tablets
BNF 0208020V0BBABAB Marevan 3mg tablets
BNF 0208020V0AAABAB Warfarin 3mg tablets
BNF 0208020AABBACAC Lixiana 60mg tablets
BNF 0208020Z0BBABAB Eliquis 5mg tablets
BNF 0208020V0BBAAAA Marevan 1mg tablets
BNF 0208020Z0BBAAAA Eliquis 2.5mg tablets
BNF 0208020Y0BBADAD Xarelto 2.5mg tablets
BNF 0208020H0BBAAAA Sinthrome 1mg tablets
BNF 0208020Y0BBAEAE Xarelto 15mg / 20mg treatment initiation pack
BNF 0208020V0AAANAN Warfarin 1mg/5ml oral liquid
BNF 0208020Z0AAABAB Apixaban 5mg tablets
BNF 0208020Y0BBACAC Xarelto 20mg tablets
BNF 0208020S0BBAAAA Marcoumar 3mg tablets
BNF 0208020AAAAAAAA Edoxaban 15mg tablets
BNF 0208020X0BBAAAA Pradaxa 75mg capsules
BNF 0208020AAAAABAB Edoxaban 30mg tablets
BNF 0208020AAAAACAC Edoxaban 60mg tablets
BNF 0208020Y0BBABAB Xarelto 15mg tablets
BNF 0208020V0AAADAD Warfarin 5mg tablets
BNF 0208020AABBABAB Lixiana 30mg tablets
BNF 0208020V0BBACAD Marevan 5mg tablets
BNF 0208020S0AAAAAA Phenprocoumon 3mg tablets
BNF 0208020N0AAAAAA Phenindione 10mg tablets
BNF 0208020X0BBABAB Pradaxa 110mg capsules

Publication

Rochelle Knight, Venexia Walker, Samantha Ip, Jennifer A Cooper, Thomas Bolton, Spencer Keene, Rachel Denholm, Ashley Akbari, Hoda Abbasizanjani, Fatemeh Torabi, Efosa Omigie, Sam Hollings, Teri-Louise North, Renin Toms, Emanuele Di Angelantonio, Spiros Denaxas, Johan H Thygesen, Christopher Tomlinson, Ben Bray, Craig J Smith, Mark Barber, George Davey Smith, Nishi Chaturvedi, Cathie Sudlow, William N Whiteley, Angela Wood, Jonathan A C Sterne, for the CVD-COVID-UK/COVID-IMPACT consortium and the Longitudinal Health and Wellbeing COVID-19 National Core Study. Association of COVID-19 with arterial and venous vascular diseases: a population-wide cohort study of 48 million adults in England and Wales

medRxiv 2021.11.22.21266512; doi: https://doi.org/10.1101/2021.11.22.21266512